1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. AKUMS DRUGS & PHARMACEUTICALS LTD.
Akums Drugs & Pharmaceuticals Ltd.
NSE: AKUMS | BSE: 544222

Akums Drugs & Pharma Live Share Price Today, Share Analysis and Chart

aboutAkums Drugs & Pharmaceuticals Ltd. is a dominant player in the Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector. The company provides end-to-end solutions, from formulation development and bio-equivalence st... Read More
US FDA InspectionsANDA Approvals
Ask AI about Akums Drugs & Pharma
716.50-5.70(-0.79%)
76,014
NSE+BSE Volume

NSE 17 Nov, 2026 10:53 AM (IST)

Portfolio

Alert

My Notes

Akums Drugs & Pharma Stock Price Analysis

Day Price Range

-0.8% 1 Day return
716.5 (LTP)
711.4727.8
LowHigh

Week Price Range

-6.4% 1 Week return
716.5 (LTP)
711.4779.3
LowHigh

Month Price Range

-2.0% 1 Month return
716.5 (LTP)
658806.4
LowHigh

52 Week Price Range

68.9% 1 Year return
716.5 (LTP)
409.3838.8
LowHigh

Akums Drugs & Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

EPS forecast

CURRENT EPS
16.7
AVG. ESTIMATE
28.6
LOW ESTIMATE
28.4
HIGH ESTIMATE
28.8
CURRENT EPS
AVG. ESTIMATE

Consensus Recommendation

3 ANALYST Recommendations
STRONG BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Akums Drugs & Pharma Technical Analysis

Akums Drugs & Pharma EMA & SMA

Bearish-6
1 bullish, 7 bearish
Bullish1
Bearish7
5 Day740.6
10 Day742.5
12 Day742.3
20 Day743.3
26 Day744.9
50 Day743.9
100 Day713.6
200 Day655.6

Akums Drugs & Pharma Delivery And Volume

Daily Avg. Delivery Volume %
16 Nov, 202631.2%
Week48.0%
Month40.5%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Akums Drugs & Pharma Resistance and Support

729.95
Pivot
First Resistance742.7
Second Resistance763.1
Third Resistance775.8
First Support709.5
Second Support696.8
Third Support676.4
Day RSI43.6
Day MACD-2.6
Day MFI69.4
Day MACD Signal Line-4.3

Akums Drugs & Pharma Beta

1 Month0.6
1 Year0.8
3 Month0.4
3 Year-

Akums Drugs & Pharma Price Change Analysis

↓-2.6%
Over 1 Month
LowHigh
658806.5
↓-2.0%
Over 3 Months
LowHigh
658838.8
↑37.8%
Over 6 Months
LowHigh
505.6838.8
↑67.9%
Over 1 Year
LowHigh
409.3838.8

Akums Drugs & Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Akums Master Trust (Sanjeev Jain And Sandeep Jain)Promoter64,200,00040.8 %
Franklin India Opportunites FundDii6,143,4583.9 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Akums Drugs & Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
RUBY QC INVESTMENT HOLDINGS PTE.LTD.BlockSell22 Dec 20254287,278,535NSE
ICICI PRUDENTIAL MUTUAL FUNDBlockPurchase22 Dec 20254287,278,535NSE
RUBY QC INVESTMENT HOLDINGS PTE.LTD.BulkSell22 Dec 20254287,278,535NSE
ICICI PRUDENTIAL MUTUAL FUNDBulkPurchase22 Dec 20254287,278,535NSE
SMALLCAP WORLD FUND INCBulkPurchase06 Aug 2024753.842,586,541NSE

Akums Drugs & Pharma Corporate Actions

Akums Drugs & Pharma Dividend history and yield

Akums Drugs & Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Akums Drugs & Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
103 Jul 2026
1FINAL03 Jul 2026Equity Share
203 Jul 2026
2SPECIAL03 Jul 2026Equity Share

Akums Drugs & Pharma Board Meetings

Akums Drugs & Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
102 Nov 2026
Quarterly Results-
208 Aug 2026
Quarterly Results-
314 May 2026
Audited Results & Final Dividend-
413 Feb 2026
Quarterly Results-
513 Nov 2025
Quarterly Results-

Akums Drugs & Pharma Research Reports

Akums Drugs & Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
103 Nov 2026ICICI Securities Limited
Target
925751.5Buy23.09%-4.66%pdf
210 Aug 2026ICICI Securities Limited
Target
850760.95Buy11.7%-5.84%pdf
316 Feb 2026ICICI Securities Limited
Target
680489.95Buy38.79%46.24%pdf
421 Dec 2025ICICI Securities Limited
Target
600443.15Buy35.39%61.68%pdf
514 Nov 2025ICICI Securities Limited565424.3Buy33.16%68.87%pdf

Akums Drugs & Pharma Corporate Filings

Akums Drugs & Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
10 Nov 2026
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Investors/Analysts Meet
PDF
05 Nov 2026
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026
PDF
03 Nov 2026
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earning/ Quarterly Conference Call
PDF
03 Nov 2026
Akums Drugs and Pharmaceuticals Ltd - 544222 - Newspaper Publication
Newspaper Publication
PDF
03 Nov 2026
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Final Report of CRISIL Ratings Limited, Monitoring Agency
PDF

Akums Drugs & Pharma Documents

Akums Drugs & Pharma Earnings Call

Akums Drugs & Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
05 Nov 2026Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
03 Nov 2026Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13 Aug 2026Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
10 Aug 2026Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10 Aug 2026Akums Drugs & Pharmaceuticals Results Earnings Call for Q1FY27

Akums Drugs & Pharma Annual Reports

Akums Drugs & Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026
2025Annual Report Mar-2025

Akums Drugs & Pharma Credit Ratings

Akums Drugs & Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
09 Apr 2026icra ratingsAkums Drugs & Pharmaceuticals LimitedRatings reaffirmed for bank facilities and assigned for commercial paper programme
08 Apr 2025icra ratingsAkums Drugs & Pharmaceuticals LimitedRatings reaffirmed
30 Jan 2025icra ratingsAkums Drugs & Pharmaceuticals LimitedUpdate on material Event
08 Oct 2024icra ratingsAkums Drugs & Pharmaceuticals LimitedLong-term rating upgraded to [ICRA]AA(Stable); short-term rating reaffirmed

Akums Drugs & Pharma Investor Presentations

Akums Drugs & Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
02 Nov 2026Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation
08 Aug 2026Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation
14 May 2026Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation
13 Feb 2026Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation
13 Nov 2025Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation

Akums Drugs & Pharma - Company Profile

Akums Drugs & Pharma Management Structure

Akums Drugs & Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Sumeet SoodChief Financial Officer211.32Mar 26
Sanjay SinhaExecutive Director,Whole Time Director,President142.82Mar 26
DHARAMVIR MALIKCompany Secretary,Compliance Officer30.44Mar 26
Mr. Sunil JaiswalSenior Vice President(Research & Development)-Mar 26
Mr. Raj Kumar SinghAssistant Vice President(Drug Regulatory Affairs)-Mar 26
Mr. Tarun KapoorSenior Vice President(IT)-Mar 26
Dr. Shantanu Rajaram ChobhePresident(CQA Formulation)-Mar 26
Mr. Vinayak BhatVice President(Operations API division)-Mar 26
Mr. V JagannathanPresident(Human Resources)-Mar 26
Sanjay KumarPresident(Operation.),Senior Management Personnel-Mar 26

Akums Drugs & Pharma Board of Directors

Akums Drugs & Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
SANJEEV JAINED / MD / Promoter866.2Mar 26
SANDEEP JAINED / MD / Promoter861.9Mar 26
Sanjay SinhaWhole-time Director142.8Mar 26
DHARAMVIR MALIKCompany Sec. & Compli. Officer30.44Mar 26
Matangi GowrishankarIndependent Non Exe. Director16Mar 26
Kewal HandaIndependent Non Exe. Director15Mar 26
SATWINDER SINGHIndependent Non Exe. Director14Mar 26
Anil Kumar Arvindlal AminIndependent Non Exe. Director9Mar 26
SUNIL KUMAR THAKURNon-Exec & Non-Independent Dir-Mar 26

About the company - Business Profile

Akums Drugs & Pharmaceuticals Ltd. is a dominant player in the Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector. The company provides end-to-end solutions, from formulation development and bio-equivalence studies to manufacturing and regulatory compliance. With a presence in over 70 countries, it serves a large client base, including major domestic and international pharmaceutical companies.

Key Points

Key Facts and Operations

  • Founded: Incorporated in April 2004.
  • Headquarters: New Delhi, India.
  • Listing: The company completed its Initial Public Offering (IPO) in August 2024 and is listed on the NSE and BSE.
  • Manufacturing Assets: Operates 14 manufacturing facilities (as of March 2025), including 11 for CDMO and 3 for Active Pharmaceutical Ingredients (API). Major sites are located in Haridwar, Kotdwar, and Baddi.
  • Infrastructure: Notable assets include a new injectable facility in Haridwar (commenced 2024) and recent land acquisitions in Jammu for future plant expansion.
  • R&D: Operates an R&D lab in Mumbai and holds over 21,000 SKUs across diverse therapeutic segments.

Business Model and Segment Performance Akums operates through a cost-plus business model for its CDMO segment, making its margins sensitive to fluctuations in raw material prices. It excels in delivering high-volume, complex dosage forms like injectable/sterile products, hormonal treatments, and nutraceuticals.

Revenue Breakdown (FY 2024-25) The company reported a total revenue of INR 4,118.20 Crores for the fiscal year ended March 31, 2025.

Business Segment Revenue (INR Cr) EBITDA Margin (%)
CDMO 3,209.1* 13.03%
API 219.0 -19.52%
Branded & Generic Formulations 690.8* 14.05%

\Segment revenue derived from reported segment results and margins in annual data.*

Market and Strategic Significance

  • Market Share: While industry volumes in the Indian Pharmaceutical Market (IPM) remained muted (1.2% growth in Q3FY26), Akums achieved double-digit volume growth in the same period.
  • Global Reach: Exports are a major focus, with facilities holding accreditations from EU-GMP, ANVISA (Brazil), and NSF (US).
  • Operational Trends: API prices fell by 8-10% YoY in 2025, impacting absolute EBITDA due to the cost-plus nature of the CDMO business. However, the company is seeing operating leverage play out as capacity utilization reached 47% by Q3FY26.

Innovation and Future Outlook

  • Technology Advancements: The company utilizes proprietary delivery systems such as FAST ABSOL, Spornam Technology, and Entroseal. It is actively expanding into differentiated dosage forms like lyophilized vials, pre-filled syringes, and gummies.
  • Sustainability & Strategic Initiatives: Current initiatives include the ramp-up of the new injectable facility in Haridwar (adding vial and LVP FFS lines) and rationalizing the portfolio in the loss-making API and trade generics segments.
  • Financial Health: Following the IPO, the debt-equity ratio improved to 0.00 as of March 2025 (from 0.69 in 2024), indicating a significantly de-leveraged balance sheet.
References
  1. Annual Report May 2025
  2. Investor Presentation Feb 2026
  3. Investor Presentation Nov 2025

Akums Drugs & Pharma FAQ

Akums Drugs & Pharma today is trading in the red, down by 0.79% at ₹716.5.
Akums Drugs & Pharma is currently trading down 0.79% on an intraday basis. In the past week the stock fell 6.44%. Stock has been down 1.39% in the past quarter and rose 68.87% in the past year. You can view this in the share price history/seasonality section.
Akums Drugs & Pharma is listed on NSE with the ticker AKUMS and on BSE as 544222. It's currently trading on NSE at a share price of ₹716.5 and on BSE with a share price of ₹713.45.
The market cap of Akums Drugs & Pharma is ₹11,277.28 Cr. as of Nov 17, 2026.
Akums Drugs & Pharma announced a FINAL dividend of 50% which equals ₹1 in Jul 03, 2026.The last ex-date for Akums Drugs & Pharma was Jul 03, 2026. To view the full dividend history of Akums Drugs & Pharma click here.
Akums Drugs & Pharma has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Akums Drugs & Pharma reported ₹1,371.29 Cr. in revenue, ₹112.85 Cr. in net profit, and ₹223.63 Cr. in EBITD as of Nov 02, 2026 for Q2 FY26-27.
According to the predictions of 3 analysts, the share price prediction for Akums Drugs & Pharma is ₹915 with an upside of 28%.
The PE ratio of Akums Drugs & Pharma is 31 as of Nov 17, 2026.
The PB ratio of Akums Drugs & Pharma is 3.3 as of Nov 17, 2026.
You can view the latest analyst reports on the Akums Drugs & Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.